Telomir Pharmaceuticals, Inc. Common Stock

Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics that target upstream biological drivers of aging and age-related diseases. Its lead candidate, Telomir-1, is an oral small-molecule metal ion regulator intended to protect against conditions such as Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, epigenetic regulation, Alzheimer's disease, and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Incorporated in 2021, it is headquartered in Miami, Florida.